Counselors in Eufaula, AL Accepting Medicare

4 Counselors found. Showing 1 - 4

Dr. Melissa Marie Chovan, LPC, LCPC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 231 East Barbour St., Eufaula, AL 36027 Phone: 334-845-4044

Alissa Evans, ALC Counselor Medicare: Not Enrolled in Medicare Practice Location: 2489 County Road 79 S, Eufaula, AL 36027 Phone: 334-845-4044

Rashanda Foster Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 39 Deerfield Dr, Eufaula, AL 36027 Phone: 334-695-1127

Katherine Kaelin Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 231 E Barbour St, Eufaula, AL 36027 Phone: 334-845-4044

News Archive

LehmanMillet honored with four prestigious industry awards

HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced it has won four prestigious industry awards: an MM&M (Medical Marketing & Media Magazine) Gold Award for work done on behalf of Abbott Nutrition; a First Place DxMA (Diagnostic Marketing Association) award for work done on behalf of Abbott Diagnostics; a First Place DxMA Award for work done on behalf of BRAHMS USA; and a PM360 Pharma Choice Bronze Award.

Ultrafast photodynamics of DNA

DNA, the molecule that acts as the carrier of genetic information in all forms of life, is highly resistant against alteration by ultraviolet light, but understanding the mechanism for its photostability presents some puzzling problems. A key aspect is the interaction between the four chemical bases that make up the DNA molecule.

Esteem hearing system receives FDA approval for treatment of sensorineural hearing loss

The U.S. Food and Drug Administration today announced the approval of the Esteem – an implanted hearing system used to treat moderate to severe sensorineural hearing loss, a type of permanent hearing loss.

Novexel commences comparative study of NXL103 to oral linezolid

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid.

Researchers find strong relationship between prenatal PAH exposure and behavioral impairment

Researchers at the Institute for the Developing Mind at Children's Hospital Los Angeles and colleagues at Columbia University's Center for Children's Environmental Health have found a powerful relationship between prenatal PAH exposure and disturbances in parts of the brain that support information processing and behavioral control.

Read more Medical News

› Verified 5 days ago